

# Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data

Joseph A Lasky, Gerard J Criner, Howard M Lazarus, Veronika Kohlbrenner, Shaun Bender and Luca Richeldi

## BACKGROUND

Nintedanib is a drug used to treat idiopathic pulmonary fibrosis (IPF).

## AIM

Look at adverse events in patients with IPF given nintedanib by their doctor.

## CONCLUSION

The safety profile of nintedanib in patients with IPF in real life is consistent with that seen in clinical trials and described in the information provided with the drug. Healthcare professionals can help patients to manage the side-effects of nintedanib therapy.


## MAIN FINDINGS



Total exposure to nintedanib was estimated as **60,107 patient-years**.



The most common adverse event reported was **diarrhea**.



Almost all (97%) of the diarrhea events were **non-serious**.



The average time between starting treatment and first having diarrhea was **60 days**.



Rarer adverse events reported included **increases in liver enzymes** detected in blood tests and **bleeding**.